The adoption of the World Health Organization Pandemic Agreement in May 2025 marked a political commitment to stronger global pandemic preparedness. Its credibility, however, depends on the successful negotiation and implementation of the Pathogen Access and Benefit Sharing annex under Article 12, to be finalized by April 2026. The COVID 19 pandemic exposed the failures of voluntary global health mechanisms, as African countries rapidly shared pathogen samples and sequence data yet faced severe delays in access to vaccines, diagnostics, and therapeutics. The PABS annex therefore represents the core test of whether the Agreement can move beyond symbolic equity toward enforceable obligations. This commentary argues that African countries enter the PABS negotiations with an unusual convergence of leverage: early scientific contributions, expanding regulatory and manufacturing capacity, and coordinated diplomacy through the African Union and Africa CDC. In a fragmented multilateral environment dominated by high income state interests, the central challenge is not recognition but conversion of capacity into binding rules. African negotiators have responded by pushing for standardized contracts, traceability of pathogen materials and sequence information, and compliance mechanisms that condition access on enforceable benefit sharing. Drawing on Africa’s institutional readiness, the paper contends that the continent is positioned not merely to influence the PABS annex, but to co-design its operational architecture. Whether this potential is realized will determine if the Pandemic Agreement corrects past inequities or reproduces them under a new legal form.
Nelson Aghogho Evaborhene (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: